A Department of Health and Human Services spokesperson called the move "a radical departure from past practices." ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Considering the bioequivalence study of Brexpiprazole Tablets 0.25mg /0.5 mg/1mg/2mg/3mg/4mg, the Subject Expert Committee ...

AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Tempus AI has announced that it is using the TIME Network to support Phase I trials and expedite site activation and ...

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

Nearly two in three people with fatty liver disease lost some of the liver fat and inflammation after using semaglutide 2.4 ...